Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis

doi:10.1038/bcj.2016.13

. 2016 Mar 11;6(3):e405.

doi: 10.1038/bcj.2016.13.

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis

A Tefferi¹, A Al-Kali¹, K H Begna¹, M M Patnaik¹, T L Lasho¹, A Rizo², Y Wan², C A Hanson³

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Janssen Research & Development, LLC, Raritan, NJ, USA.
³ Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.

PMID: 26967822
PMCID: PMC4817097
DOI: 10.1038/bcj.2016.13

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis

A Tefferi et al. Blood Cancer J. 2016.

. 2016 Mar 11;6(3):e405.

doi: 10.1038/bcj.2016.13.

Authors

A Tefferi¹, A Al-Kali¹, K H Begna¹, M M Patnaik¹, T L Lasho¹, A Rizo², Y Wan², C A Hanson³

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Janssen Research & Development, LLC, Raritan, NJ, USA.
³ Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.

PMID: 26967822
PMCID: PMC4817097
DOI: 10.1038/bcj.2016.13

No abstract available

PubMed Disclaimer

Conflict of interest statement

AR and YW are employees of and hold stock in Janssen. The remaining authors declare no conflict of interest.

Figures

**Figure 1**
Effect of imetelstat on hemoglobin (Hgb), platelet and leukocyte counts in three patients with refractory anemia with ring sideroblasts with (ex178520) or without (ex176837 and ex178418) thrombocytosis. ex176837: T1 duration=28 weeks and treatment ongoing; ex178418: T1 duration=37 weeks and treatment ongoing; ex178520: T1 duration=9 weeks and off-study July 2014. ANC, absolute neutrophil; WBC, white blood cell.

See this image and copyright information in PMC

Cited by

Telomerase-targeted therapies in myeloid malignancies.
Waksal JA, Bruedigam C, Komrokji RS, Jamieson CHM, Mascarenhas JO. Waksal JA, et al. Blood Adv. 2023 Aug 22;7(16):4302-4314. doi: 10.1182/bloodadvances.2023009903. Blood Adv. 2023. PMID: 37216228 Free PMC article. Review.
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
Patnaik MM, Tefferi A. Patnaik MM, et al. Am J Hematol. 2019 Apr;94(4):475-488. doi: 10.1002/ajh.25397. Epub 2019 Jan 24. Am J Hematol. 2019. PMID: 30618061 Free PMC article. Review.
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia.
Bruedigam C, Porter AH, Song A, Vroeg In de Wei G, Stoll T, Straube J, Cooper L, Cheng G, Kahl VFS, Sobinoff AP, Ling VY, Jebaraj BMC, Janardhanan Y, Haldar R, Bray LJ, Bullinger L, Heidel FH, Kennedy GA, Hill MM, Pickett HA, Abdel-Wahab O, Hartel G, Lane SW. Bruedigam C, et al. Nat Cancer. 2024 Jan;5(1):47-65. doi: 10.1038/s43018-023-00653-5. Epub 2023 Oct 30. Nat Cancer. 2024. PMID: 37904045 Free PMC article. Clinical Trial.
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
Patnaik MM, Tefferi A. Patnaik MM, et al. Am J Hematol. 2017 Mar;92(3):297-310. doi: 10.1002/ajh.24637. Am J Hematol. 2017. PMID: 28188970 Free PMC article. Review.
Biological and clinical implications of telomere dysfunction in myeloid malignancies.
Kishtagari A, Watts J. Kishtagari A, et al. Ther Adv Hematol. 2017 Nov;8(11):317-326. doi: 10.1177/2040620717731549. Epub 2017 Oct 6. Ther Adv Hematol. 2017. PMID: 29093807 Free PMC article. Review.

See all "Cited by" articles

References

1. Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015; 373: 908–919. - PubMed
1. Broseus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013; 27: 1826–1831. - PubMed
1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951. - PubMed
1. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

[1] Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015; 373: 908–919. - PubMed

[2] Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015; 373: 908–919. - PubMed

[3] Broseus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013; 27: 1826–1831. - PubMed

[4] Broseus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013; 27: 1826–1831. - PubMed

[5] Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951. - PubMed

[6] Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951. - PubMed

[7] Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674. - PubMed

[8] Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis

Affiliations

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources